Live
- VIP Treatment: Exclusive Benefits for High Rollers in Online Casino
- LS polls: Union Minister Bhagwanth Khuba, Dingaleshwara seer, Priyanka Jarkiholi file nominations in K'taka
- Amid show of strength, Congress’ Praniti Shinde files nomination from Solapur
- Tamil Nadu Police gives clean report to Isha Foundation in missing volunteers case
- Home Minister Amit Shah to address public meeting in Goa on April 24
- Gurgaon Open: M Dharma fires 67 for two-shot lead on penultimate day
- Sharad Pawar made many attempts to finish Shiv Sena, claims Maha minister
- Former England opener Raman Subba Row dies aged 92
- IPL 2024: Impact player rule is affecting the progress of half all-rounders, says Zaheer Khan
- ‘Teppa samudram’ review: Entertains with twists and turns
RLS gets DCGI nod for Corona drug Favipiravir
RLS gets DCGI nod for Corona drug Favipiravir
City-based Raghava Life Sciences Limited (RLS) on Monday said it received Drug Controller General of India (DCGI) approval to manufacture and market bulk drug (API) for Favipiravir which is being widely used for the treatment of Covid-19
Hyderabad: City-based Raghava Life Sciences Limited (RLS) on Monday said it received Drug Controller General of India (DCGI) approval to manufacture and market bulk drug (API) for Favipiravir which is being widely used for the treatment of Covid-19.
RLS Managing Director P Lohit Reddy said that pharma companies such as Lupin, Hetero, Cipla and Sun Pharma recently launched oral pills of favipiravir under their own brands at competitive prices.
"Favipiravir is being widely considered successful in treating Covid patients. The medicine is currently being prescribed to Covid-19 patients with mild to moderate symptoms.
A data from clinical trials involving 150 subjects showed that about 70 per cent of the patients being treated with the drug achieved clinical cure by the fourth day of the study, compared with about 45 per cent in the standard care group," Reddy said.
Advanced stage trials of favipiravir are currently underway in several countries including India. RLS, which also specializes in contract research projects, received approval to supply the active pharmaceutical ingredient (API) of the drug to formulation companies.
